BeiGene Gears Up For Cancer Immunology Debut
This article was originally published in PharmAsia News
Executive Summary
After entering three drug candidates to clinical stage, securing first round financing and obtaining milestone payments from Merck Serono, BeiGene has eyed unveiling a cancer immunology pipeline and a potential listing on the NASDAQ.